US 12,233,034 B2
Formulations for epidermal repair
Cheryl Lee Eberting, Alpine, UT (US)
Assigned to Claridei Laboratories, Inc., Alpine, UT (US)
Filed by Claridei Laboratories, Inc., Alpine, UT (US)
Filed on Oct. 4, 2021, as Appl. No. 17/493,801.
Application 17/493,801 is a continuation of application No. 16/008,786, filed on Jun. 14, 2018, granted, now 11,135,184.
Application 16/008,786 is a continuation of application No. 14/907,479, abandoned, previously published as PCT/US2014/048226, filed on Jul. 25, 2014.
Claims priority of provisional application 62/005,702, filed on May 30, 2014.
Claims priority of provisional application 61/968,078, filed on Mar. 20, 2014.
Claims priority of provisional application 61/896,215, filed on Oct. 28, 2013.
Claims priority of provisional application 61/858,513, filed on Jul. 25, 2013.
Prior Publication US 2022/0031640 A1, Feb. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 8/365 (2006.01); A61K 8/36 (2006.01); A61K 8/37 (2006.01); A61K 8/41 (2006.01); A61K 8/42 (2006.01); A61K 8/44 (2006.01); A61K 8/49 (2006.01); A61K 8/55 (2006.01); A61K 8/63 (2006.01); A61K 8/68 (2006.01); A61K 9/00 (2006.01); A61K 31/133 (2006.01); A61K 31/164 (2006.01); A61K 31/19 (2006.01); A61K 31/20 (2006.01); A61K 31/23 (2006.01); A61K 31/455 (2006.01); A61K 31/573 (2006.01); A61K 31/575 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/24 (2006.01); A61K 47/28 (2006.01); A61Q 19/00 (2006.01)
CPC A61K 31/164 (2013.01) [A61K 8/361 (2013.01); A61K 8/365 (2013.01); A61K 8/37 (2013.01); A61K 8/41 (2013.01); A61K 8/42 (2013.01); A61K 8/44 (2013.01); A61K 8/4926 (2013.01); A61K 8/55 (2013.01); A61K 8/63 (2013.01); A61K 8/68 (2013.01); A61K 9/0014 (2013.01); A61K 31/133 (2013.01); A61K 31/19 (2013.01); A61K 31/20 (2013.01); A61K 31/23 (2013.01); A61K 31/455 (2013.01); A61K 31/573 (2013.01); A61K 31/575 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/18 (2013.01); A61K 47/24 (2013.01); A61K 47/28 (2013.01); A61Q 19/00 (2013.01); A61Q 19/007 (2013.01); A61K 2800/48 (2013.01); A61K 2800/5922 (2013.01)] 20 Claims
 
1. A composition comprising therapeutically effective amounts of at least one of each of the following:
18β-glycyrrhetinic acid;
a glucocorticoid;
a ceramide;
polyhydroxy acid to maintain a pH of 4.6-5.6;
a therapeutically effective amount of niacinamide; and
a chelating agent.